{"id":"NCT00769860","sponsor":"Richard Barohn, MD","briefTitle":"Arimoclomol in Sporadic Inclusion Body Myositis","officialTitle":"Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-09","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2008-10-09","resultsPosted":"2017-01-19","lastUpdate":"2017-01-19"},"enrollment":24,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Inclusion Body Myositis"],"interventions":[{"type":"DRUG","name":"Arimoclomol","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"ACTIVE_COMPARATOR"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.","primaryOutcome":{"measure":"Count of Adverse Events Reported","timeFrame":"Month 12","effectByArm":[{"arm":"Arimoclomol","deltaMin":109,"sd":null},{"arm":"Placebo","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":2,"countries":["United States","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Fall/contusion","Constipation","Upper respiratory tract infection","Musculoskeletal pain","Loose stools"]}}